AfroCentric Investment Corporation Limited Overview
AfroCentric is a JSE-listed, Sanlam-controlled healthcare investment holding company. Its core asset is Medscheme, one of South Africa's longest-established medical scheme administrators and managed care providers (55 years old on 1 March 2026). Around Medscheme sit specialist risk businesses:
-
Aid for AIDS (HIV disease management)
-
DENIS (dental capitation)
-
Scriptpharm (pharmacy benefit and oncology risk management)
-
Pharmacy Direct, a courier pharmacy that delivers about 1.4 million public-sector chronic scripts per month under the Department of Health's CCMDD programme
The Group managed about 4.09 million lives in FY2025. That base fell to about 3.3 million after Bonitas Medical Fund, its largest client for 43–44 years, moved administration to Momentum Health and managed care to Private Health Administrators (PHA) on 1 June 2026.
The investment case has shifted from a growth-oriented healthcare ecosystem within Sanlam to a turnaround. The turnaround rests on four levers:
-
a cost reset after a R1.37bn impairment year
-
disposal of non-core pharmaceutical manufacturing (Activo, completed August 2026)
-
defence of the remaining scheme book
-
a pivot toward capitation and value-based care
Company's own description (FY2025 Directors' Report and H1 2026 results). AfroCentric describes itself as a JSE-listed investment holding company. It operates in, and provides specialised services to, the public and private healthcare sectors, with the aim of making quality healthcare more accessible and affordable to members and beneficiaries [S1]. Its stated principal objective is to deliver efficient health management services and quality products at manageable and affordable cost. In its 2026 interim materials, the Group describes its offering as integrated health management solutions: medical scheme administration, managed care, medicine provision, wellness services and digital health innovations, across public and private sectors [S5].
Independent characterisation. AfroCentric is in substance a B2B healthcare services outsourcer with three economic engines.
-
Fee-based scheme administration and managed care (the core).
-
Medscheme earns contracted per-member-per-month (PMPM) administration and managed care fees from medical schemes. These are non-profit, member-owned funds regulated by the Council for Medical Schemes (CMS).
-
Revenue is annuity-like but tied to tender cycles, typically 3–5-year contracts, and to scheme membership.
-
The model is labour- and IT-intensive. Employee benefit costs were R2,795m, or 38% of FY2025 continuing revenue [S1].
-
-
Risk-bearing capitation businesses.
-
DENIS (dental), Scriptpharm (chronic, HIV and oncology medicine) and the new spinal-care risk transfer model take on utilisation risk for a fixed capitation fee.
-
Capitation fund revenue was R834m in H1 2026, against capitation expenses of R825m [S4]. Margins depend on actuarial pricing and claims control.
-
Management cites these lines as its highest-quality earnings. DENIS operational earnings grew 26.2% and Scriptpharm oncology profitability grew 29% in FY2025 [S6].
-
-
Pharmaceutical distribution (retail cluster).
-
Pharmacy Direct, a courier pharmacy serving private scheme members and the public sector via CCMDD, plus Curasana (wholesale).
-
This is a high-volume, thin-margin, working-capital-intensive business. Courier trading margin fell from 6.8% in 2024 to 2.2% in 2025 [S6].
-
Activo (generic manufacturing and marketing) was sold to Portugal's FHC Group effective 31 August 2026 [S4].
-
Revenue model mix (H1 2026, continuing operations; total R3,485.4m) [S4]:
About 88% of revenue is service or contract revenue recognised over time. About 12% is product revenue recognised at a point in time [S4].
Value chain position. AfroCentric sits between funders (medical schemes, government programmes, employers) and providers (hospitals, doctors, pharmacies). It performs:
-
claims adjudication (about 10.2 million provider claim lines per month, more than 99% auto-adjudicated) [S7]
-
pre-authorisation and case management
-
disease management
-
provider network contracting
-
fraud, waste and abuse detection
-
medicine dispensing and logistics
Customer types.
-
Open medical schemes, such as Fedhealth and Medshield. Bonitas was a client until 31 May 2026.
-
Restricted (employer) schemes, including GEMS (a managed care client), POLMED (administered since 2016) and Sisonke (from 1 May 2026) [S18][S22][S34].
-
The national and provincial Departments of Health (CCMDD).
-
Corporate employers (onsite clinics, wellness, EAP, gap and primary care cover).
-
Individual members (gap cover via a Sanlam/Centriq cell).
Medscheme had 14 medical scheme clients as at January 2026, including GEMS [S18].
End-markets.
-
South African private medical scheme administration and managed care.
-
Public-sector chronic medicine distribution.
-
Employee health and wellness.
-
Selected Southern African markets: Namibia, Mauritius, Botswana (via an associate) and Eswatini. FY2025 Africa revenue was R261m [S6].
Strategy
Stated strategy (FY2025 Integrated Report, "Vision 2030"). The strategy rests on four objectives [S7][S8]:
-
Building a winning health offering in partnership with Sanlam.
-
Driving clinical innovation, through value-based care and capitation risk transfer.
-
Investing in data, digital and technology.
-
Evolving culture and the operating model.
The stated purpose is "enhancing the quality of life of our stakeholders". The vision is "transforming healthcare". The mission is to innovate an integrated, sustainable healthcare model that measurably improves access [S8].
Sanlam collaboration goals (FY2025 Directors' Report) [S1]:
-
A health-to-wealth-to-protection client proposition.
-
A holistic corporate wellness model with Sanlam Corporate Services.
-
Growth and retention of scheme membership.
-
Growth and retention of the gap and primary health insurance books.
Post-Bonitas turnaround programme (H1 2026) [S4]:
The Board's original four response priorities were [S17]:
-
Restructure to the new revenue reality.
-
Protect the core (3.3m beneficiaries).
-
Reorganise the operating model.
-
Simplify the portfolio.
The H1 2026 results expanded these into six execution priorities:
-
Protect service delivery and client confidence.
-
Complete the Bonitas wind-down responsibly.
-
Realign the cost base to future scale.
-
Redesign organisational structures and support functions.
-
Simplify the portfolio.
-
Sequence strategic investment by affordability and measurable value.
The 2026 interim commentary states that the immediate priority is "no longer growth at legacy scale" but stabilisation, cash preservation and restoring sustainable earnings [S4].
Initiatives in the last 24 months
| Initiative | Date | Status / target | Source |
|---|---|---|---|
| Strategy refresh and operating model review | FY2024–FY2025 | Completed. Capability-based delivery model in place. | [S11b], [S7] |
| Orthocare Spinal Risk Transfer pilot (Fedhealth, Medshield) | 1 Jan 2025 | Break-even in the pilot phase; to be scaled | [S6] |
| Integrated PBM (Medscheme + Scriptpharm) | 2,025 | Ongoing integration | [S7] |
| Pharma cluster cost rationalisation | Apr 2025 | Pharmacy Direct and Curasana operating profit up from R1.3m to R35.7m (H1 2025 vs H1 2026) | [S6], [S4] |
| Data centre relocation; new AfroCentric Technologies platform | Apr 2025 | Completed | [S7] |
| Core claims and pre-authorisation replacement (decision engine); RPA/AI | 2024–2026 | 89% end-to-end automation on targeted workflows | [S7] |
| Contact centre modernisation (AI engagement platform) | 2025–2026 | Implementation under way | [S7] |
| ADS / Wellworx sale to Sanlam; distribution via Sanlam Health Distribution | Jul 2025 | Completed | [S6] |
| Health Rewards by Sanlam (Fedhealth app) | 2025/26 | Live. Enhanced loyalty milestone planned for 2027. | [S4] |
| Credit Gateway (employee financial wellbeing) | 2,025 | Launched | [S7] |
| Activo disposal | Dec 2025 – Aug 2026 | Completed 31 Aug 2026 | [S4] |
| Section 189A restructuring (Bonitas-servicing staff) | H1 2026 | Executed; termination costs taken in H1 2026 | [S4] |
| Broker portal relaunch | 2,026 | Scheduled | [S7] |
| Capital preservation (no FY2025 dividend) | Mar 2026 | Board policy for the short to medium term | [S6] |
ESG commitments. Level 1 B-BBEE maintained. Specific emissions or sustainability targets were not located in the sources reviewed.
Cost programme targets. Quantified savings targets are not publicly disclosed.
Medium-term financial targets and guidance. Not publicly disclosed. Management has guided only qualitatively: it expects the operating environment to remain challenging, with the full financial impact of the contract loss continuing to show in future reporting periods [S4].
Products & Services
Detailed specifications and pricing are not published for most products. Where pricing is not disclosed, the pricing model is inferred from the revenue line under which the product is reported [S4].
Medical scheme administration, risk management and technology cluster
| Offering | Description | Target customer | Launch / status | Pricing model |
|---|---|---|---|---|
| Medscheme – scheme administration | Membership, contributions, claims processing, provider payment, call centres and regulatory reporting for medical schemes. About 10.2m provider claim lines per month, more than 99% automated. 76% automation on about 150,000 hospital claims per month. | Open and restricted medical schemes (14 scheme clients as at Jan 2026, including GEMS; POLMED; Fedhealth; Medshield; Sisonke from May 2026) | Operating since 1971 | PMPM administration fees, under 3–5-year tender contracts |
| Medscheme – managed care / health risk management | Hospital pre-authorisation, case management, chronic and disease management, PMB management, mental health admissions, clinical protocols | Medical schemes | Ongoing | PMPM managed care fees |
| Aid for AIDS (AfA) | HIV/AIDS disease management programme | Medical schemes (managed care) | Long-standing | Managed care fees |
| Orthocare Spinal Risk Transfer Model | Multidisciplinary biopsychosocial pathway for chronic lower back pain, aimed at reducing unnecessary spinal surgery. Pilots in Fedhealth and Medshield reached break-even. | Medical schemes | Launched 1 Jan 2025 | Risk transfer / capitation |
| Oncology Performance-Based Reimbursement Model | Outcome-linked oncology treatment pathways | Medical schemes | Ongoing | Performance-based reimbursement |
| Fraud, waste, abuse and error programmes (historically "Medscheme Forensic Services" and "Insurance Fraud Manager") | Claims oversight and provider billing analytics | Schemes and insurers | Ongoing | Fees / shared savings (not disclosed) |
| DENIS (Dental Information Systems) | Dental benefit management and dental capitation. FY2025 operational earnings +26.2%. | Medical schemes | Acquired FY2021 | Capitation |
| Klinikka | Health administration / managed care subsidiary listed among group companies. Detailed product scope not publicly disclosed. | — | — | — |
| AfroCentric Technologies | Core administration platforms ("Nexus and other healthcare administration systems", carrying value R897.5m at Jun 2026), a real-time rules-based decision engine, Enterprise Data Exchange, and RPA/AI (87 processes, 130 bots, about 240,000 work items per month) | Internal (Medscheme) and external IT revenue | Ongoing modernisation. New platform adopted 2025. Data centres relocated April 2025. | Intercompany IT fees; segment revenue R675.5m in FY2025 |
| Provider portal | Claims review, benefit verification and remittances. 35,775+ practices and 245 bureaus. | Healthcare providers | Launched Jul 2024 | Bundled |
| QR point-of-care tool | Deployed at 516 practice locations (3,251 scans) | Members and providers | 2,025 | Bundled |
| Broker portal (redesigned) | Reporting, product mapping and onboarding. Real-time quotes planned. | Intermediaries | Launch scheduled 2026 | Bundled |
| Health Rewards by Sanlam | Digital health engagement and rewards in the Fedhealth member app. Enhanced loyalty milestone planned for 2027. | Fedhealth members | Launched 2025/26 | — |
| Medscheme Namibia / Namibia Health Risk Solutions / Medscheme Mauritius | Administration and managed care outside South Africa. Namibia membership grew about 2% in 2025. | Schemes in Namibia, Mauritius and others | Ongoing | Administration fees (R110m in H1 2026) |
| Associated Fund Administrators (Botswana) | Associate company, scheme administration in Botswana | Botswana schemes | Associate | Equity-accounted |
Sources: [S4][S6][S7][S17][S18][S22].
Pharmaceutical cluster
| Offering | Description | Target customer | Status | Pricing model |
|---|---|---|---|---|
| Pharmacy Direct – Public (CCMDD) | Courier dispensing and distribution of chronic medication for the Department of Health's Central Chronic Medicines Dispensing and Distribution programme. 1.417m scripts per month in FY2025 (up 6.6%), serving 2.4m+ patients. Integrated with the SyNCH platform. | National and provincial Departments of Health | Record volumes in FY2025 | Per-script fee (declining price per script) |
| Pharmacy Direct – Private | Courier pharmacy for scheme members, integrated with Medscheme and AfA for real-time chronic authorisations. 105,560 scripts per month in FY2025, down from 157,759. | Medical scheme members (DSP arrangements) | Lost Bonitas DSP status (Feb 2025) | Script dispensing fee plus product margin |
| Curasana Wholesalers | Pharmaceutical wholesale | Pharmacies | Ongoing | Wholesale margin |
| Scriptpharm Risk Management | Pharmacy benefit management, formulary and compliance management (more than 90% generic substitution), chronic, HIV and oncology capitation. Delivered savings of R69m (chronic) and R240m (HIV) for two schemes, and R65m (oncology) for a large scheme. | Medical schemes | Lost Bonitas medicine management contract from 1 Jun 2026 | Capitation and risk-sharing |
| Activo Health / Forrester Pharma / Activo Healthcare Assets (discontinued) | Generic medicines (OTC, antiretrovirals, acute and chronic), vitamins and nutraceuticals | Retail pharmacy, the state, GEMS (historically) | Sold to FHC Group, 31 Aug 2026 | Product sales |
Sources: [S4][S6][S7][S26].
Corporate solutions cluster
| Offering | Description | Target customer | Status | Pricing model |
|---|---|---|---|---|
| AfroCentric Workcare / Employee Health Solutions | Nurse-led onsite clinics and mobile nurse services. Online booking and InBody scanners planned. | Employers | Ongoing | Service fees |
| AfroCentric Wellness / The Cheese Has Moved | Digital wellness, mental health support, gamified engagement, WhatsApp channels, anonymised employer analytics | Employers | Ongoing | Fees |
| Credit Gateway | Employee debt management and financial wellbeing | Employers / employees | Launched 2025 | — |
| Sanlam Gap Cover (cell captive via Centriq Insurance) | Gap cover, with automated gap claims integrated with Medscheme-administered schemes. Carrying value R87.7m at Jun 2026. | Individuals and employer groups | Ongoing | Insurance premiums (insurance revenue R74.3m in H1 2026) |
| Medgap Cover (Guardrisk cell) | Gap cover | Individuals | Ceased underwriting 1 Jul 2025; cell closed 30 Jun 2026 | — |
| AfroCentric Health Insure / Essential Medical (EssentialMED) / AfroCentric Integrated Health Administrators / AfroCentric Integrated Solutions | Primary health insurance, gap products and integrated administration | Low-to-middle income market, employers | Ongoing | Premiums / fees |
| Fedhealth Elect and Savvy + Sanlam Primary Care bundles | Low-cost scheme options combined with unlimited primary care outside hospital | Employers | Ongoing | Packaged |
| Warona Health Emergency Medical Services, Allegra, Memo Digital | Listed group entities. Product details not publicly disclosed. | — | — | — |
Sources: [S1][S4][S7].
Divested distribution offerings. AfroCentric Distribution Services, Tendahealth, AfroCentric Financial Services and Wellworx were sold to Sanlam Life in July 2025. The distribution function now operates as Sanlam Health Distribution within Sanlam Corporate Distribution [S6][S7].
Financial Narrative
Income statement, five years
Reported basis; R m unless stated. FY2021–FY2024 are years to 30 June. FY2025 is the year to 31 December, on a continuing-operations basis excluding Activo.
Sources and notes:
-
FY2021/FY2022: SENS 13 Sep 2022 [S13]. FY2023 (restated) and FY2024: SENS 3 Sep 2024 [S12]. FY2025: AFS and SENS 4 Mar 2026 [S1][S2].
-
Diluted EPS for FY2021–FY2024 is not separately reported in the short-form announcements; basic EPS is shown as a proxy.
-
Dividends per share follow the payment history: interim plus final for FY2021 and FY2022; an 11c interim for FY2024; nil for FY2025 [S31][S14][S1].
-
FY2023 headline earnings per press reporting was R217.3m restated, against an originally reported HEPS of 36.2c [S16].
Transition period, 6M to 31 Dec 2024 (not included above):
-
Revenue R3,765.4m (re-presented for continuing operations; originally R4,240.9m).
-
Profit before tax R225.1m.
-
Basic loss R125.9m.
-
Headline earnings R31.9m.
-
HEPS 3.80c, EPS (14.96)c, dividend 6c.
Sources: [S1][S2][S11].
Gross profit. Not reported. The statement of profit or loss is presented by nature, not function. FY2025 product cost of sales (cost of pharmaceutical products R804.2m plus distribution R57.3m) against retail segment revenue gives a retail gross margin of about 36% on a segment basis. This is an analyst computation from [S1][S4].
Margins
These are analyst calculations.
FY2025 non-IFRS operating profit was R678.8m, a 9.1% margin on segment revenue of R7,446.8m [S4]. The company cites "R679 million in operational earnings" [S6].
Earlier operating profit. Full-year non-IFRS operating profit for FY2021–FY2024 was not located in the sources reviewed. FY2020 operating profit was R960.7m on revenue of R6,441m (14.9%) [S15].
Revenue CAGR:
-
FY2021–FY2024 (comparable June years): about +2.9% per year.
-
FY2021–FY2025 (not like-for-like, because FY2025 excludes about R1.1bn of Activo revenue): about −2.5% per year.
Balance sheet
Sources: [S1][S4][S2].
-
NAV per share for Jun-2025 and Jun-2026 is an analyst calculation: attributable equity divided by 840.7m shares.
-
Borrowings comprise a Nedbank facility (R598.9m at Jun 2026) and a Bank Windhoek mortgage loan (R27.8m) [S4].
-
Assets held for sale (Activo) were R566.0m at Dec 2025 and R592.2m at Jun 2026, including R179.5m of cash at Jun 2026 [S1][S4].
Goodwill composition:
The remaining intangible base is dominated by self-generated administration systems (R897.5m at Jun 2026) [S4].
Cash flow
Sources: [S1][S4]. Free cash flow is an analyst definition, because AfroCentric classifies dividends paid within operating activities.
Historical half-year cash generation. Cash generated from operations (excluding dividends) was R520m (Dec 2021), R270m (Dec 2022), R409m (Dec 2023), R604m (Jun 2024), R456m (Jun 2025) and R262m (Jun 2026) [S9b][S4].
Ratios (FY2025, analyst computations from [S1])
Commentary on trends, inflections and drivers.
-
FY2021–FY2022: Covid tailwinds and acquisition-led growth.
-
Revenue rose 25.8% in FY2021 and 8% in FY2022. The drivers were the full-year inclusion of DENIS, additional GEMS managed care services, and pandemic-era pharmaceutical and vaccination demand [S40][S37].
-
Headline earnings peaked at R329m (FY2021).
-
The dividend was 34c, covered about 1.6–1.7x by HEPS.
-
-
FY2023: normalisation and the change of control.
-
Pharma cluster operating profit fell 41.1% as OTC and HIV medicine sales normalised, chronic adherence dropped, and supply instability hit Activo [S16].
-
The weighted share count rose by about 39% in FY2024 after the Sanlam asset-for-share transaction (AHA minority swapped into AfroCentric equity). HEPS was therefore diluted even as minorities' share of Medscheme profits was eliminated.
-
-
FY2024: impairment cycle begins.
-
R230m of impairments, including R130m on the Activo and Forrester investment of about R868m [S12]. Reported profit fell 75%.
-
Headline earnings rose 54% because of the full-year benefit of the AHA minority buy-in.
-
-
Transition (6M Dec 2024) and FY2025: Bonitas erosion and a goodwill reset.
-
The loss of Bonitas DSP status (Feb 2025) cut private scripts by 33% and antiretroviral volumes by 40.5% [S6].
-
After Bonitas's 29 January 2026 award to competitors, management impaired goodwill and intangibles. The total was R1.37bn across continuing and discontinued operations, including R810.9m of continuing goodwill and R227.6m in discontinued operations [S1][S6].
-
Underlying performance was resilient: operating cash generation of R914.8m and adjusted EBITDA of about R700m.
-
-
H1 2026: post-Bonitas reset begins.
-
Revenue fell 5.6% and HEPS fell 26.9% to 8.54c.
-
Continuing profit before tax still rose 25.9% to R111.4m, on cost containment and lower amortisation [S4].
-
The balance sheet moved to net cash (excluding leases) of R84m. The R300m revolving credit facility is undrawn [S4].
-
The full-year earnings impact of losing Bonitas falls in H2 2026 and FY2027. Bonitas paid roughly R1.1bn of administration fees and about R660m of managed care fees in 2024, based on CMS data [S19]. Management has not disclosed the exact revenue share.
-
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Segment Overview
| Segment | What it contains |
|---|---|
Healthcare SA | Medscheme administration and managed care, Aid for AIDS, Klinikka, corporate solutions entities, gap and primary care insurance |
DENIS Group | Dental benefit management and dental capitation |
Information Technology | AfroCentric Technologies, which runs core administration platforms (the "Nexus" administration systems), decision engine and automation |
Total SA administration business | The sum of the three segments above |
Healthcare Africa | Medscheme Namibia, Namibia Health Risk Solutions, Medscheme Mauritius and other Southern African operations |
Healthcare Retail | Pharmacy Direct, Curasana, Scriptpharm. The Activo Group was previously included and is now discontinued. |
Segment revenue (ZAR Mn)
| Segment revenue (ZAR Mn) | H1 2025 | H1 2026 |
|---|---|---|
Healthcare SA | 2,123.0 | 2,163.7 |
DENIS Group | 301.5 | 314.2 |
Information Technology | 338.0 | 346.0 |
Total SA administration | 2,762.5 | 2,823.9 |
Healthcare Africa | 129.6 | 121.0 |
Total Group administration | 2,892.1 | 2,944.9 |
Pharmacy Direct and Curasana | 640.3 | 484.6 |
Scriptpharm | 702.3 | 642.7 |
Healthcare Retail total | 1,342.5 | 1,127.2 |
Inter-segment eliminations | -473.3 | -512.3 |
Group total (incl. insurance revenue) | 3,761.3 | 3,559.8 |
Segment operating profit (ZAR Mn)
| Segment operating profit (ZAR Mn) | H1 2025 | H1 2026 |
|---|---|---|
Healthcare SA | 99.6 | 50.8 |
DENIS Group | 19.7 | 30.6 |
Information Technology | 112.0 | 92.9 |
Total SA administration | 231.4 | 174.3 |
Healthcare Africa | 42.7 | 47.4 |
Total Group administration | 274.1 | 221.7 |
Pharmacy Direct and Curasana | 1.3 | 35.7 |
Scriptpharm | 33.7 | 24.7 |
Healthcare Retail total | 35.1 | 60.4 |
Group operating profit | 309.2 | 282.2 |
Segment Overview — Healthcare SA
| Segment | Revenue (ZAR Mn) | Operating profit (ZAR Mn) | Op. margin (%) | % of pre-elimination revenue | Pre-tax profit/(loss) (ZAR Mn) |
|---|---|---|---|---|---|
Healthcare SA | 4,292.7 | 304.5 | 7.1 | 46.6 | (1,340.9) |
DENIS Group | 601.6 | 57.2 | 9.5 | 6.5 | 59.2 |
Information Technology | 675.5 | 123.6 | 18.3 | 7.3 | (113.8) |
Total SA administration | 5,569.8 | 485.3 | 8.7 | 60.5 | (1,395.5) |
Healthcare Africa | 261.3 | 91.6 | 35.1 | 2.8 | 87.3 |
Total Group administration | 5,831.1 | 576.9 | 9.9 | 63.3 | (1,308.2) |
Pharmacy Direct and Curasana | 1,982.6 | 37.7 | 1.9 | 21.5 | 105.1 |
Scriptpharm | 1,397.2 | 64.2 | 4.6 | 15.2 | 80.9 |
Healthcare Retail | 3,379.8 | 101.9 | 3.0 | 36.7 | 186.0 |
Eliminations / other | (1,764.0) | — | — | — | 590.3 |
Group | 7,446.8 | 678.8 | 9.1 | 100.0 | (531.9) |
Income Statement and Per-Share Data
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue from contracts with customers (ZAR Mn) | 8,074.4 | 8,722.6 | 8,760.2 | 8,794.7 | 7,303.2 |
Profit before tax (ZAR Mn) | 699.5 | 675.2 | 427.4 | 207.0 | -531.9 |
Profit for the year incl. discontinued (ZAR Mn) | 469.7 | 481.7 | 295.5 | 74.3 | -1,259.2 |
Basic earnings attributable (ZAR Mn) | 302.0 | 314.3 | 183.5 | 55.4 | -1,274.2 |
Headline earnings (ZAR Mn) | 329.1 | 317.1 | 217.3 | 334.8 | 117.1 |
Basic EPS (ZAR cents) | 52.56 | 54.57 | 30.70 | 6.67 | -151.55 |
Headline EPS (ZAR cents) | 57.26 | 55.07 | 36.34 | 40.32 | 13.92 |
Diluted EPS (ZAR cents) | 52.56 | 54.57 | 30.70 | 6.67 | -149.41 |
Dividends per share (ZAR cents) | 34 | 34 | 0 | 11 | 0 |
Weighted average shares (millions) | 574.7 | 575.9 | 597.8 | 830.3 | 840.75 |
Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Pre-tax margin (%) | 8.7 | 7.7 | 4.9 | 2.4 | -7.3 |
Net margin incl. discontinued (%) | 5.8 | 5.5 | 3.4 | 0.8 | -17.2 |
Headline earnings margin (%) | 4.1 | 3.6 | 2.5 | 3.8 | 1.6 |
Step Details
| Step | R m |
|---|---|
Reported loss before tax (continuing) | -531.9 |
Add finance costs plus lease interest | +75.5 |
Less finance income | -55.0 |
Add depreciation, right-of-use depreciation and amortisation (124.0 + 60.1 + 202.1) | +386.2 |
Reported EBITDA | -125.4 |
Add back impairments (goodwill 810.9, intangibles 11.2, PPE 1.3, right-of-use 1.5) | +824.9 |
Adjusted EBITDA | ≈699.5 |
Balance Sheet and Per-Share Data
| Metric (ZAR Mn) | Dec-2024 | Jun-2025 | Dec-2025 | Jun-2026 |
|---|---|---|---|---|
Total assets | 5,162.5 | 5,449.4 | 4,180.5 | 3,986.8 |
Cash and cash equivalents (excl. held for sale) | 347.8 | 483.2 | 607.4 | 710.9 |
Borrowings – current | 62.4 | 72.2 | 53.1 | 49.8 |
Borrowings – non-current | 556.7 | 582.1 | 574.1 | 576.9 |
Total borrowings | 619.1 | 654.2 | 627.2 | 626.7 |
Lease liabilities | 171.7 | 144.3 | 116.4 | 130.5 |
Net debt excl. leases | 271.3 | 171.1 | 19.9 | -84.2 |
Net debt incl. leases | 443.0 | 315.4 | 136.3 | 46.3 |
Total equity | 3,279.1 | 3,329.8 | 1,943.0 | 2,016.9 |
Equity attributable to owners | 3,245.7 | 3,289.9 | 1,902.8 | 1,975.6 |
Goodwill and intangible assets | 2,541.4 | 2,501.3 | 1,047.6 | 1,004.2 |
Working capital (current assets less current liabilities, excl. held for sale) | 559.6 | 610.7 | 263.4 | 321.5 |
NAV per share (ZAR cents) | 390 | 391 | 231 | 235 |
Returns & Leverage Ratios
| Goodwill (ZAR Mn) | Jun-2025 | Jun-2026 |
|---|---|---|
AfroCentric Health | 705.3 | 30.0 |
Pharmacy Direct and Curasana | 140.6 | 5.0 |
DENIS | 34.9 | 34.9 |
Activo and Activo Healthcare Assets | 227.6 | nil (held for sale) |
Total | 1,108.5 | 69.9 |
Cash Flow
| Metric (ZAR Mn) | 6M-Dec-2024 | FY2025 | H1-2026 |
|---|---|---|---|
Cash generated from operations | 343.2 | 914.8 | 262.2 |
Net cash from operating activities | 249.3 | 684.9 | 218.2 |
Capex – property and equipment | 64.5 | 96.5 | 25.3 |
Capex – intangible assets | 70.5 | 122.9 | 8.9 |
Total capex | 135.0 | 219.3 | 34.2 |
Dividends paid (incl. to non-controlling interests) | 4.6 | 58.5 | 3.9 |
Share buybacks | 1.1 | 0.0 | 0.0 |
Free cash flow (net operating CF + dividends paid − capex) | 118.9 | 524.1 | 187.9 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2025 | Basis |
|---|---|---|
ROE (attributable loss / average attributable equity) | -49.5% | Loss of R1,274.2m ÷ average equity of R2,574.3m |
Headline ROE | 4.5% | Headline earnings of R117.1m ÷ R2,574.3m |
ROA (loss / average total assets) | -27.0% | Loss of R1,259.2m ÷ R4,671.5m |
ROIC (adjusted) | ≈11% | Adjusted EBIT R313.3m × (1 − 27%) ÷ year-end invested capital ≈ R2,079m |
Current ratio (excl. held for sale) | 1.21x | Dec 2024: 1.58x |
Current ratio (incl. held for sale) | 1.54x | — |
Debt / equity (borrowings only) | 0.32x | Dec 2024: 0.19x |
Net debt / adjusted EBITDA (incl. leases) | 0.19x | R136.3m ÷ R699.5m |
Interest coverage (adjusted EBIT / finance costs incl. leases) | ≈4.1x | R313.3m ÷ R75.5m |
Asset turnover | 1.56x | Revenue ÷ average total assets |
Receivable days | ≈26 days | R521.1m ÷ R7,303.2m × 365 |
Inventory days (on product cost of sales) | ≈45 days | R107.3m ÷ R861.4m × 365 |
Cash conversion cycle | Not meaningful / not disclosed | The predominantly service business and the held-for-sale reclassification distort payables metrics |
Revenue by geography (ZAR Mn)
| Revenue by geography (ZAR Mn) | H1-2025 | FY2025 | H1-2026 |
|---|---|---|---|
South Africa | 3,564.1 | 7,041.9 | 3,364.5 |
Outside South Africa (Healthcare Africa) | 129.6 | 261.3 | 121.0 |
Group revenue from contracts with customers | 3,693.6 | 7,303.2 | 3,485.4 |
Segment Overview (2)
| Segment | South Africa | Outside SA | Total |
|---|---|---|---|
Healthcare SA | 2,403.5 | — | 2,403.5 |
Healthcare Africa | — | 121.0 | 121.0 |
Healthcare Retail | 1,127.2 | — | 1,127.2 |
Information Technology | 346.0 | — | 346.0 |
Intercompany eliminations | (512.3) | — | (512.3) |
Group | 3,364.5 | 121.0 | 3,485.4 |
Share price metric (ZAR cents)
| Share price metric (ZAR cents) | Jun-2021 | Jun-2022 | Jun-2023 | Jun-2024 | Dec-2024 | Oct-2026 |
|---|---|---|---|---|---|---|
Period-end share price (ZAR cents) | 442 | 439 | 415 | 288 | 199 | 66 |
Market Valuation
| Market capitalisation (ZAR Mn) | Dec-2023 | Dec-2024 | Jul-2025 | Oct-2026 |
|---|---|---|---|---|
Market capitalisation (ZAR Mn) | 2,732.7 | 1,673.8 | 1,420.0 | 555.1 |
Start Point by Horizon
| Horizon | Start point | Change |
|---|---|---|
≈5-year | Jun 2021 (442c) | −85% |
≈3-year | Jun 2023 (415c) | −84% |
≈15-month | Jul 2025 (169c) | −61% |
Valuation Snapshot
| Multiple | Value | Basis |
|---|---|---|
Price / headline earnings (FY2025) | 4.7x | HEPS 13.92c |
Price / headline earnings (trailing 12m to Jun 2026) | 6.1x | HEPS ≈10.78c (13.92 − 11.68 + 8.54) |
P/B | 0.28x | NAV ≈235c at Jun 2026 |
EV | ≈R643m | Market cap 555.1 + borrowings 626.7 + leases 130.5 + non-controlling interests 41.3 − cash 710.9 |
EV / Sales (FY2025) | 0.09x | — |
EV / adjusted EBITDA (FY2025) | 0.92x | ≈R699.5m. Forward EBITDA will be materially lower after Bonitas, so this multiple overstates cheapness. |
Ex-date Details
| Ex-date | Amount (ZAR cents) | Period |
|---|---|---|
11 Nov 2020 | 17 | Final FY2020 |
12 May 2021 | 17 | Interim FY2021 |
10 Nov 2021 | 17 | Final FY2021 |
11 May 2022 | 17 | Interim FY2022 |
9 Nov 2022 | 17 | Final FY2022 |
8 May 2024 | 11 | Interim (6M Dec 2023) |
7 May 2025 | 6 | 6M Dec 2024 |
| — | nil | FY2025 (capital preservation) |
Analyst Conclusions
Management guidance. There is no quantitative guidance. The Board expects a "challenging" environment while it completes the Bonitas wind-down, organisational redesign, cost reset and portfolio simplification. It explicitly flags that the full financial impact of the contract loss will appear in future periods [S4].
Consensus. Not publicly available.
Bull case
-
The cost reset can protect earnings faster than revenue falls.
-
H1 2026 continuing PBT rose 25.9% on a 5.6% revenue decline [S4].
-
The Bonitas fee pool (≈R1.76bn per year by CMS-based estimates) carried substantial dedicated cost, now being removed through Section 189A [S19][S4].
-
-
The balance sheet and valuation offer a margin of safety.
-
Net cash excluding leases, plus an undrawn R300m revolving credit facility.
-
Shares at about 0.28x book and below 1x trailing adjusted EBITDA on EV.
-
Activo deferred consideration (≈R196m) still to flow in [S4].
-
-
A higher-quality earnings mix. The specialist capitation businesses (DENIS, oncology, spinal) and Healthcare Africa (35% margin) are growing. The integrated Sanlam proposition could win restricted-scheme and employer mandates, as Sisonke shows [S4][S6].
Bear case
-
The revenue cliff is not yet in the numbers. Only one month of Bonitas loss falls in H1 2026. Healthcare SA operating profit already halved to R50.8m [S4].
-
Contract churn may continue. Management cites tighter procurement cycles and several renewals in 2025 [S7]. The Bonitas dispute may weigh on reputation with trustees, while Discovery and the enlarged Momentum gain scale [S33].
-
Minority shareholders are structurally disadvantaged.
-
Sanlam controls 58.81% and carries the stake at nil in its own books [S24].
-
Related-party disposals were done at NAV (ADS) [S4].
-
Dividends are suspended and liquidity is thin.
-
The R897.5m software intangible base remains subject to impairment testing [S1][S4].
-
Key catalysts and monitorables (next 12 months)
-
FY2026 trading statement and results (expected around Feb–Mar 2027). Watch the full H2 impact of Bonitas, restructuring savings and any further software or goodwill impairments.
-
New business wins or losses at upcoming scheme tenders, and retention of GEMS, POLMED and Fedhealth.
-
Outcome of the CMS Section 44 investigation into Bonitas and any regulatory findings.
-
Activo deferred consideration and earnout settlement, and use of proceeds.
-
Sanlam's intentions. Possible capital support, a minority buy-out or further asset transfers (none announced).
-
Dividend reinstatement policy and capital allocation under the "sequencing" framework.
-
Pharmacy Direct CCMDD contract terms and pricing, and NHI legislative progress.
-
Headcount and cost disclosures that quantify the reset.
Analyst verdict
AfroCentric enters late 2026 as a fundamentally changed business. For most of the past decade the equity story was a healthcare ecosystem built around Medscheme's scale and Bonitas's anchor contract, with pharmaceutical integration and Sanlam distribution as accelerants. That story has broken in three steps:
-
The pharmaceutical integration failed. Activo was bought out at R588m, impaired twice and sold for an expected value of about R285m.
-
The Bonitas relationship ended after 43–44 years, taking with it roughly 680,000–750,000 beneficiaries and an estimated R1.7bn-plus of annual fees.
-
A R1.37bn impairment reset cut NAV per share from 390c to 231c in a single year.
What remains is smaller but more coherent and, on the evidence, cash-generative:
-
A retained base of about 3.3m lives.
-
A highly automated administration platform.
-
Profitable specialist capitation lines.
-
A Southern African business earning 35% margins.
-
A public-sector courier pharmacy with record volumes.
The balance sheet is ungeared on a net basis, liquidity is ample, and the parent is publicly committed.
The investment question is whether the cost base can be cut to match the post-Bonitas revenue line before further contract attrition occurs. H1 2026 is encouraging on cost discipline: continuing PBT rose despite falling revenue. But H1 2026 contains only one month of the Bonitas loss, so FY2026 and H1 2027 are the real tests.
At about R555m market capitalisation, 0.28x book and about 6x trailing headline earnings, the market is pricing in sustained decline. That pricing looks overly punitive if management stabilises the scheme book and delivers the cost reset. It looks fair if a second large client defects.
The minority shareholder's position is constrained. Sanlam controls the outcome, liquidity is thin, dividends are suspended, and any value-crystallising event (a buy-out or restructuring) is at the parent's discretion.
Verdict: a high-risk, deep-value special situation. Visibility is lowest until the FY2026 results confirm the post-Bonitas earnings run-rate.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure | Prior roles | Education | Total compensation |
|---|---|---|---|---|---|
Gerald (GN) van Wyk | Group CEO, executive director | Joined 1 Aug 2023; CEO from 1 Nov 2023 | CEO Client Solutions, Santam; Executive Head Strategic Business Development, Santam; roles at Discovery Insure, Mutual & Federal and Hollard; former chair of Indwe Broker Holdings; past president of the Insurance Institute of Gauteng | BCom Risk Management (Unisa); MDP (Stellenbosch); GMP (Harvard) | — |
Thato (KT) Moloele | Group CFO, executive director | CFO-designate 1 Jan 2025; CFO from 1 Feb 2025 | — | CA(SA) | — |
Andrew (AD) Schwulst | CEO, Medscheme (subsidiary) | From 2023 | Former CEO, Liberty Health | — | R5.717m (FY2025, total cost to company plus incentives) |
Lebohang Mpumlwana | Group Company Secretary | — | — | — | — |
Bongiwe Ncube | General Manager: Group Finance | — | — | CA(SA) | — |
“—” = not publicly disclosed.
Executive Leadership Team by Executive
| Executive | Total cost to company and incentives |
|---|---|
D Carolus | 6,236 (includes a 36-month retention bonus with clawback) |
AD Schwulst | 5,717 |
AA Mahmood | 5,073 |
FV Nompumza | 5,062 |
MS Bray | 4,303 |
Board of Directors
| Director | Role | Appointed | FY2025 fees (ZAR K) | Notes |
|---|---|---|---|---|
Prof Anna (ATM) Mokgokong | Chairman, non-executive | 10 Jun 2010 | 2,039 | Indirect holding of 3.96% |
José Bruno Fernandes | Lead Independent NED; Chair of Audit and Risk Committee | 23 Nov 2018 | 1,438 | CA(SA) |
Alice Marie le Roux | Independent NED; Audit and Risk Committee member | 25 May 2020 | 896 | CA(SA) & RA |
Karabo Morule | Independent NED; Audit and Risk Committee member | 31 Dec 2024 | 738 | Actuary (FIA, FASSA) |
CK Mokoena | Independent NED | 1 Oct 2025 | 150 | — |
MJ Madungandaba | Non-executive (former Deputy Chairman) | 10 Jun 2010 | 978 | Indirect holding of 4.94% |
Dr Nkateko (ND) Munisi | Non-executive; moved to Remuneration Committee on 24 Feb 2026 | 7 Dec 2015 | 657 | Holding of 4.41% |
Paul (PB) Hanratty | Non-executive (Sanlam Group CEO) | 12 Jun 2023 | nil | Sanlam executives are not remunerated |
KN Mkhize | Non-executive (Sanlam) | 20 Jun 2022 | nil | — |
Zakhe Zuma | Director; Investment Committee member | 17 Sep 2026 | — | ARC principal transactor. |
Gerald van Wyk | Executive (CEO) | 1 Aug 2023 | — | — |
Thato Moloele | Executive (CFO) | 1 Jan 2025 | — | — |
Major Shareholders
| Holder | Shares | % |
|---|---|---|
Sanlam Life Insurance Limited (strategic) | 494,431,629 | 58.81 |
Community Healthcare Holdings (Pty) Ltd (director-associated) | 74,098,672 | 8.81 |
ARC Financial Services Investments (Pty) Ltd | 62,912,483 | 7.48 |
Visio Capital Management | 47,730,220 | 5.68 |
Definitive Capital Management | 2,702,525 | 0.32 |
Pershing Securities Limited | 1,608,114 | 0.19 |
Bank Julius Baer & Co | 665,019 | 0.08 |
Peresec Prime Brokers | 573,196 | 0.07 |
Nedbank Private Wealth | 349,912 | 0.04 |
Barnard Jacobs Mellet | 244,641 | 0.03 |
Investec Private Clients | 131,827 | 0.02 |
Melville Douglas Investment Management | 120,000 | 0.01 |
Competitive Landscape
Market Share by Competitor
| Competitor | Segment(s) | Relative positioning vs AfroCentric | Revenue / share data (verified) |
|---|---|---|---|
Discovery Health (Discovery Ltd) | Scheme administration, managed care | Dominant open-scheme administrator; highest admin fee (R387.08 pampm, 2024) | DHMS 33.1% of principal members (2024). |
Momentum Health Solutions (Momentum Group) | Administration, managed care | Now administers Bonitas; ≈30% administration market share post-win | Momentum targets FY2027 normalised headline earnings of R7bn (group) |
Private Health Administrators (PHA) | Managed care | Won the Bonitas managed care mandate; named in procurement allegations | — |
Agile Business Solutions | Scheme marketing and distribution | Won the Bonitas marketing tender from ADS (2024) | — |
Medihelp (self-administered scheme) | Administration (in-house) | Former POLMED administrator | — |
Bestmed (self-administered scheme) | Administration (in-house) | Lowest managed care cost among large schemes (R116.11 pmpm) | — |
3Sixty Health | Administration | Mid-tier administrator | — |
Universal Healthcare | Administration and managed care | Mid-tier administrator | — |
Lifesense / other HIV management providers | Disease management (vs AfA) | Specialist competitor | — |
Dental benefit managers (e.g., Dental Risk Company) | Dental capitation (vs DENIS) | Specialist competitor | — |
Courier and chronic medicine distributors (e.g., Medipost; retail pharmacy chains Clicks and Dis-Chem) | Courier pharmacy, CCMDD (vs Pharmacy Direct) | Pharmacy Direct is self-described as the country's largest courier pharmacy | — |
“—” = not publicly disclosed.
Peer Comparison FY2025
| Metric | AfroCentric (FY2025) | Sanlam (parent, context) |
|---|---|---|
Revenue | R7.3bn (continuing) | — |
Revenue growth | Not comparable (year-end change). H1 2026: −5.6%. | — |
Operating margin | 9.1% (non-IFRS) | — |
R&D / tech intensity | ≈1.6% capitalised software; ≈5.5% including IT opex | — |
Market cap | ≈R0.56bn (Oct 2026) | ≈R175bn (Sep 2026) |



